The development of a medicinal product is a step-by-step process that involves the evaluation of data on their efficacy and safety in both animals and humans. The goals of preclinical safety assessment typically include the characterization of toxic effects on target organs, dose dependency, exposure, and, where appropriate, potential reversibility. This information is used to determine the initial safe dose and range of doses in human studies, and to determine the parameters for clinical monitoring of potential adverse effects.
Pre-clinical studies are an essential step in the obtaining of marketing authorization for:
LLC "ClinPharmInvest" successfully cooperates with Russian centers for preclinical trials meeting all modern requirements localized in Moscow, Saint Petersburg, and Yaroslavl.